Girth Control

By Rodgers, Katie | Drug Topics, May 2, 1996 | Go to article overview

Girth Control


Rodgers, Katie, Drug Topics


First weight loss Rx in 20 years clears the FDA

Redux (dexfenfluramine, Interneuron Pharmaceuticals), a serotonergic appetite suppressant, has received Food & Drug Administration approval for the management of obesity in patients on a reduced-calorie diet. It is approved for both initial weight loss and maintenance of weight loss, so pharmacists can expect to see it used long-term. The first appetite suppressant to clear the FDA in 20 years, dexfenfluramine has been available in Europe for more than a decade and has been used by an estimated 10 million patients.

Dexfenfluramine appears to increase serotonin levels by three different mechanisms. Robert Kushner, M.D., director of the Nutrition and Weight Control Clinic at the University of Chicago, explained that, like the selective serotonin reuptake inhibitors, dexfenfluramine also inhibits the reuptake of serotonin. In addition, it releases serotonin into the synaptic cleft and decreases presynaptic uptake. "So, it not only releases it, but it reduces uptake into the presynaptic and postsynaptic neuron," he said. Increased serotonin levels are associated with decreased caloric intake.

In a one-year clinical trial of 900 obese patients, those who dieted and took dexfenfluramine lost significantly more weight than patients who dieted and took placebo. At the end of one year, 64% of the patients maintained on dexfenfluramine lost at least 5% of their initial weight, 40% lost at least 10%, and 21% lost at least 15%.

Dexfenfluramine was also shown to be beneficial in a study of 60 obese patients who had already lost an average of 10 pounds on diet alone. The addition of dexfenfluramine resulted in a further 26% reduction of initial excess weight.

In the clinical trials, the most common adverse events were diarrhea (17.5%), dry mouth (12.5%), and somnolence (7.1%). The side effects were mild and abated with continued use.

Dexfenfluramine has been classified as a Schedule IV controlled substance, but the drug will probably be "descheduled" later this year. Dexfenfluramine is contraindicated for use in patients with pulmonary hypertension. In patients using anorexiants, primary pulmonary hypertension has been shown to occur at the rate of 18 cases per one million users per year, up from two to three cases per year per one million people in the general population.

Questions about the potential for dexfenfluramine to cause neurotoxicity recently prompted some neuroscientists to request the FDA to delay approving the drug. Their request was based on a study showing that rats given high doses of dexfenfluramine experienced neurochemical changes in the brain. This safety concern is addressed in the product's labeling, which points out that the doses used in the rodent study were much higher than the doses recommended for humans. …

The rest of this article is only available to active members of Questia

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Default project is now your active project.
Project items

Items saved from this article

This article has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this article

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Buy instant access to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited article

Girth Control
Settings

Settings

Typeface
Text size Smaller Larger Reset View mode
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Help
Full screen

matching results for page

    Questia reader help

    How to highlight and cite specific passages

    1. Click or tap the first word you want to select.
    2. Click or tap the last word you want to select, and you’ll see everything in between get selected.
    3. You’ll then get a menu of options like creating a highlight or a citation from that passage of text.

    OK, got it!

    Cited passage

    Style
    Citations are available only to our active members.
    Buy instant access to cite pages or passages in MLA, APA and Chicago citation styles.

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

    1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

    Cited passage

    Thanks for trying Questia!

    Please continue trying out our research tools, but please note, full functionality is available only to our active members.

    Your work will be lost once you leave this Web page.

    Buy instant access to save your work.

    Already a member? Log in now.

    Oops!

    An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.